Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2023-03-30 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
关于2023年度为子公司提供担保额度预计的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Shenzhen BGI Genomics Co., Ltd. regarding the estimated guarantee amount to be provided to its subsidiaries for the year 2023. It details the board and supervisory meetings approving the guarantee, the guarantee amount, the financial status of the subsidiaries, and the legal and procedural compliance. The document is a formal disclosure of a corporate financing-related activity (providing guarantees to subsidiaries to support their financing needs). It is not a full financial report, audit report, or earnings release. It is not a report publication announcement or a certification. The content fits best under Capital/Financing Update (CAP) as it relates to updates on company financing activities and guarantees provided to subsidiaries. The document length is sufficient and contains substantive information about the financing guarantee arrangements, not just a brief notice or a report publication announcement.
2023-03-30 Chinese
2022年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Evaluation Report" for the year 2022 by Shenzhen BGI Genomics Co., Ltd. It discusses the company's internal control systems, evaluation scope, methodology, and conclusions about the effectiveness of internal controls as of December 31, 2022. The content focuses on internal control evaluation, risk assessment, control activities, and compliance with regulatory standards. It does not contain financial statements or quarterly/yearly financial performance data typical of Annual Reports (10-K) or Interim Reports (IR). It is a standalone report on internal control evaluation, which aligns with the definition of an Audit Report / Information (AR). The document length (8498 characters) and detailed content confirm it is the report itself, not just an announcement. Therefore, the appropriate classification is AR with high confidence. FY 2022
2023-03-30 Chinese
中信证券股份有限公司关于深圳华大基因股份有限公司部分募集资金投资项目延期的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from a sponsoring institution (中信证券股份有限公司) regarding the delay in certain investment projects funded by proceeds from a specific stock issuance by 深圳华大基因股份有限公司. It includes detailed financial figures about the raised funds, their usage, project progress, reasons for delay, and official opinions from the board, independent directors, and supervisory board. The document is not a full financial report like an Annual Report or Interim Report, nor is it a brief announcement or a certification. It is a regulatory compliance and verification report related to the use of raised capital and project progress, which fits best under Regulatory Filings (RNS) as it does not match other more specific categories such as Capital/Financing Update (CAP) or Audit Report (AR). The document length is under 5,000 characters, but it contains substantive content rather than just an announcement of a report publication, so it is not RPA. Therefore, the best classification is Regulatory Filings (RNS).
2023-03-30 Chinese
关于续聘2023年度审计机构的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the reappointment of the audit firm Ernst & Young Hua Ming for the 2023 fiscal year. It details the qualifications, independence, and integrity of the audit firm and the procedures followed by the audit committee, independent directors, board of directors, and supervisory board in approving the reappointment. The document does not contain the audit report itself or detailed financial statements but is an official announcement about the audit firm appointment for the upcoming year. The document length is 4291 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document fits the category of Audit Report / Information (AR) as it relates to audit matters but is not a full annual report or audit report itself. However, since it is specifically about the appointment of the audit firm and related audit information, the best fit is Audit Report / Information (AR). FY 2023
2023-03-30 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 16th meeting of the 3rd Board of Directors of Shenzhen BGI Genomics Co., Ltd. It includes approvals of the 2022 Annual Report and its summary, the 2022 Board work report, the 2022 General Manager's report, the 2022 financial statements and 2023 budget, profit distribution plan, appointment of the 2023 audit firm, reports on fundraising use, internal control evaluation, ESG report, and other governance and operational matters. The document is a formal board meeting resolution announcement, not the full annual report itself. It references that the full 2022 Annual Report and related documents are disclosed on the CNINFO website, indicating this document is a board meeting resolution announcement rather than the report itself. The document length (8520 characters) is substantial but it is primarily a meeting resolution announcement. Therefore, the filing type is Board/Management Information (MANG).
2023-03-30 Chinese
2022年度监事会工作报告
Management Reports Classification · 95% confidence The document is titled '2022 年度监事会工作报告' which translates to '2022 Supervisory Board Work Report' of Shenzhen BGI Genomics Co., Ltd. It details the supervisory board's activities, including meetings held, oversight of financial conditions, compliance with laws and regulations, internal controls, related party transactions, asset acquisitions and disposals, guarantees, insider information management, and internal control evaluation for the year 2022. The document is a comprehensive report on the supervisory board's work and oversight for the fiscal year 2022. It is not an announcement or a brief summary but a detailed report. This type of document is typically classified as a Management Report (MDA) because it provides management's detailed explanation of company operations, financial oversight, governance, and outlook. It is not an Annual Report (10-K) or Audit Report (AR) because it focuses on supervisory board activities rather than full financial statements or audit opinions. It is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA) because it contains substantive content and is over 5,000 characters. Therefore, the best fit is Management Reports (MDA).
2023-03-30 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.